Legal & General Pharma Breakthrough UCITS ETF (BIGT)
12.75p
(1.57%)
- Add to watchlist
- Create an alert
- This stock can be held in a
12.75p
(1.57%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
12.75p
(1.57%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
813.65p
819.40p
853.00p
London
813.65p
816.29p
721.90p
849.33M
8.35p (1.04%) Previous:
8.35p
8,543
n/a
GBX
ETP Basics
| Issuer: | GO UCITS ETF Solutions Plc |
|---|---|
| Structure: | ETF |
| Replication method: | Stocks - Full Replication |
| Securities lending: | No |
| Number of holdings: | 32 |
| Size: | 849.3M |
| Launch date: | n/a |
| Launch price: | n/a |
| UCITS: | Yes |
| Reporting status: | Yes |
| Domicile: | n/a |
| Complex product: | Non-complex |
| ISIN: | IE00BF0H7608 |
Annual & interim reports
Before you invest, please make sure you read the documents below
Ready to invest?
Important Documents
There are no documents available for this stock.
OBJECTIVE
| Index: | [No Data] |
|---|---|
| Aim: |
[No Data]
Read full aim for Legal & General |
| Leverage: | 100% |
| Currency hedging: | n/a |
COSTS
| Ongoing Charge (OCF/TER): | 0.49% |
|---|---|
| Management fee: | 0.75% |
| Indicative spread: | 0.49% |
In certain cases, where no TER or OCF is shown, additional costs may apply. Please ensure you have read the Key Investor Information Document, Factsheet, Prospectus and any other relevant documentation prior to investing.
Performance
Not available for this stock.
| Security | Weight |
|---|---|
| CHUGAI PHARMACEUTICAL CO | 17.38% |
| TAKEDA PHARMACEUTICAL CO | 15.64% |
| KYOWA HAKKO KIRIN CO. | 15.26% |
| EISAI CO. | 15.00% |
| JCR PHARMACEUTICAL CO | 14.81% |
| NIPPON SHINYAKU CO | 14.55% |
| SWEDISH ORPHAN BIOVITRUM AB (PUBL) | 1.45% |
| INNOVENT BIOLOGICS INC | 1.27% |
| SINO BIOPHAMACEUTICAL | 0.98% |
| INNOCARE PHARMA LTD | 0.88% |
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.